CV Therapeutics' Ranexa gains US approval for first-line use in angina
This article was originally published in Scrip
CV Therapeutics'santi-anginal Ranexa (ranolazine extended-release tablets) has received US FDAapproval for a new, first-line indication for the treatment of chronic angina. The revised label also includes additional claims that Ranexa reduces arrhythmias – including ventricular arrhythmias, new atrial fibrillation and bradycardia – and also reduces HbA
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.